240 related articles for article (PubMed ID: 22812556)
41. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
[No Abstract] [Full Text] [Related]
42. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis.
Díaz-Borjón A
Drugs Aging; 2009; 26(4):273-93. PubMed ID: 19476397
[TBL] [Abstract][Full Text] [Related]
43. Rheumatoid arthritis and tuberculosis in the tumor necrosis factor inhibitors era: observations from Brazil.
da Rocha Castelar Pinheiro G
J Clin Rheumatol; 2005 Dec; 11(6):344-6. PubMed ID: 16371812
[No Abstract] [Full Text] [Related]
44. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
Mok CC; Tsai WC; Chen DY; Wei JC
Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
[TBL] [Abstract][Full Text] [Related]
45. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.
Ding T; Ledingham J; Luqmani R; Westlake S; Hyrich K; Lunt M; Kiely P; Bukhari M; Abernethy R; Bosworth A; Ostor A; Gadsby K; McKenna F; Finney D; Dixey J; Deighton C; ;
Rheumatology (Oxford); 2010 Nov; 49(11):2217-9. PubMed ID: 20837498
[No Abstract] [Full Text] [Related]
46. Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.
Park DJ; Choi SJ; Shin K; Kim HA; Park YB; Kang SW; Kwok SK; Kim SK; Nam EJ; Sung YK; Lee J; Lee CH; Jeon CH; Lee SS
Clin Rheumatol; 2017 May; 36(5):1013-1022. PubMed ID: 28243760
[TBL] [Abstract][Full Text] [Related]
47. Biologics and heart failure in rheumatoid arthritis: are we any wiser?
Danila MI; Patkar NM; Curtis JR; Saag KG; Teng GG
Curr Opin Rheumatol; 2008 May; 20(3):327-33. PubMed ID: 18388526
[TBL] [Abstract][Full Text] [Related]
48. Advances in use of immunomodulatory agents--a rheumatology perspective.
Her M; Kavanaugh A
Nat Rev Gastroenterol Hepatol; 2015 Jun; 12(6):363-8. PubMed ID: 25895821
[TBL] [Abstract][Full Text] [Related]
49. The perioperative use of biologic agents in patients with rheumatoid arthritis.
Polachek A; Caspi D; Elkayam O
Autoimmun Rev; 2012 Dec; 12(2):164-8. PubMed ID: 22522087
[TBL] [Abstract][Full Text] [Related]
50. [Anti-cytokine treatment, newly developed].
Hanaoka H; Takeuchi T
Nihon Rinsho; 2013 Jul; 71(7):1253-60. PubMed ID: 23961676
[TBL] [Abstract][Full Text] [Related]
51. Switching of biologics in RA patients who do not respond to the first biologic.
Durez P
Joint Bone Spine; 2018 Jul; 85(4):395-397. PubMed ID: 29452302
[No Abstract] [Full Text] [Related]
52. [Position on choice of agents among TNF inhibitors].
Manger B;
Z Rheumatol; 2005 Mar; 64(2):88-9. PubMed ID: 15793672
[No Abstract] [Full Text] [Related]
53. Cost-effectiveness of biologics in early rheumatoid arthritis.
Finckh A; Bansback N; Liang MH
Ann Intern Med; 2010 Mar; 152(5):333-4; author reply 334. PubMed ID: 20194244
[No Abstract] [Full Text] [Related]
54. Bone effects of biologic drugs in rheumatoid arthritis.
Corrado A; Neve A; Maruotti N; Cantatore FP
Clin Dev Immunol; 2013; 2013():945945. PubMed ID: 23864880
[TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
Boers M
Ann Intern Med; 2009 Nov; 151(9):668-9. PubMed ID: 19884628
[No Abstract] [Full Text] [Related]
56. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease.
Richards JS; Dowell SM; Quinones ME; Kerr GS
BMJ; 2015 Aug; 351():h3658. PubMed ID: 26282936
[TBL] [Abstract][Full Text] [Related]
57. Biologics in oral medicine: principles of use and practical considerations.
O'Neill ID; Scully C
Oral Dis; 2012 Sep; 18(6):525-36. PubMed ID: 22420757
[TBL] [Abstract][Full Text] [Related]
58. Laboratory monitoring of biologic therapies.
Cush JJ; Yazici Y
Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S90-2. PubMed ID: 16273791
[TBL] [Abstract][Full Text] [Related]
59. Biologic therapies and pregnancy: the story so far.
Hyrich KL; Verstappen SM
Rheumatology (Oxford); 2014 Aug; 53(8):1377-85. PubMed ID: 24352337
[TBL] [Abstract][Full Text] [Related]
60. Assessing infection risk with biologic agents in RA: methodological challenges.
Fisher MC; Greenberg JD
Nat Rev Rheumatol; 2009 May; 5(5):288-91. PubMed ID: 19412196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
